Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Long-term Investments

Investments the company intends to hold for more than a year.

Charles River Laboratories International, Inc.NYSE: CRL

Long-term Investments · Q2 FY2026 · quarter ended Jun 2026

Long-term investments falls 4.4% from a year ago

Long-term investments stood at $206.47M at the end of Q2 FY2026, down 4.4% from a year earlier and down 1.6% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.

Context

  • Long-term investments amounted to 2.7% of total assets at the end of Q2 FY2026, down 0.1 pp from a year earlier.
  • Long-term investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term investments keeps falling in the next quarterly balance sheet after a -4.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$206.47M-1.6% QoQ
Last fiscal yearDec 2025
$206.97M-5.2% YoY
Year agoJun 2025
$216.07M-4.4% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%——
1 year-5.2%——
3-year CAGR-12.7%——
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
206.97M USD
Year-over-year change
-5.2%
4-year CAGR
+0.7%

Long-term Investments vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's Jun 2026 long-term investments of $206.47M is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -4.4% is the lowest of 2, against a peer median of +160.1%.
  • Long-term investments amounts to 2.7% of total assets for CRL, versus a peer median of 0.0%.
CRL Competitors Peer median
Long-term Investments for CRL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRLCharles River Laboratories International, Inc.Jun 2026$206.47M -4.4%-12.7%2.7%
ICLRICON Public Limited CompanyJun 2026$176.21M +160.1%+36.0%1.1%
MEDPMedpace Holdings, Inc.Sep 2026$0 ——0.0%
CERTCertara, Inc.Mar 2026$0 ——0.0%
Peer median (excluding CRL) $0+160.1%+36.0%0.0%

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents245.24M233.91M276.77M194.61M213.77M
Short-term Investments00000
Net Receivables650.38M752.39M780.38M720.92M708.86M
Inventory199.15M255.81M380.26M278.54M299.1M
Other Current Assets0107.58M83.38M105.8M8.65M
Total Current Assets1.27B1.44B1.61B1.4B1.45B
Property, Plant & Equipment (Net)1.58B1.86B2.03B2.02B2.02B
Goodwill2.71B2.85B3.1B2.85B2.76B
Intangible Assets1.06B955.28M864.05M723.4M340M
Long-term Investments201.35M311.6M243.81M218.35M206.97M
Tax Assets40.23M41.26M40.28M42.18M67.33M
Other Non-current Assets151.54M148.28M309.38M278.23M293.19M
Total Non-current Assets5.75B6.16B6.59B6.13B5.69B
Total Assets7.02B7.6B8.2B7.53B7.14B
Account Payables198.13M205.92M168.94M140.34M148.8M
Short-term Debt101K00061.06M
Tax Payables26.16M038.8M00
Deferred Revenue219.7M264.26M241.82M248.32M210.42M
Other Current Liabilities307.01M401.65M431.04M373.43M392.19M
Total Current Liabilities1.03B1.09B1.06B994.1M1.12B
Long-term Debt2.92B2.71B2.65B2.24B2.55B
Deferred Tax Liabilities239.72M215.58M191.35M106.96M95.2M
Deferred Revenue (Non-current)20.58M00045.63M
Other Non-current Liabilities(30.69M)174.82M223.19M195.21M(341.38M)
Total Non-current Liabilities3.4B3.49B3.48B3.03B2.8B
Total Liabilities4.43B4.58B4.54B4.02B3.92B
Common Stock505K509K513K511K492K
Retained Earnings980.75M1.43B1.89B1.81B1.39B
Accumulated OCI(164.74M)(262.06M)(196.43M)(317.35M)(171.78M)
Other Stockholders Equity00000
Minority Interest57.17M47.21M62.12M46.58M46.56M
Total Equity2.59B3.02B3.66B3.51B3.21B
Total Debt3.21B3.1B3.07B2.72B3.07B
Net Debt2.96B2.86B2.79B2.53B2.85B

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.